

## Re: Manuscript for publication in Fabad Journal of Pharmaceutical Sciences

From: FABAD Ankara (fabadankara@gmail.com)

To: yuliyusrini@yahoo.com

Date: Monday, 9 September 2019 at 04:48 pm GMT+8

Dear Yulia Y. Djabir,

Your manuscript was received and given the code A592. Please use this code in the subject of your e-mails for further inquiries

Regards.

Prof. Dr. Nesrin Gökhan Kelekçi  
FABAD Journal of Pharmaceutical Sciences  
Editor

yulia yusrini djabir <[yuliyusrini@yahoo.com](mailto:yuliyusrini@yahoo.com)>, 28 Ağu 2019 Çar, 10:23 tarihinde şunu yazdı:

Thank you very much for the response.  
I have made several changes according to your instruction.  
The revised manuscript is attached below.

Best regards,

Yulia Y. Djabir  
Laboratory of Clinical Pharmacy  
Faculty of Pharmacy  
Hasanuddin University  
Makassar  
Indonesia

On Friday, 23 August 2019, 04:56:52 am GMT+8, FABAD Ankara <[fabadankara@gmail.com](mailto:fabadankara@gmail.com)> wrote:

Dear Yulia Y. Djabir,

The formal examination of your manuscript has been made. Please make corrections in your manuscript:

1. Please give 6 (six) keywords.
2. Please write et al. in normal letters. Do not write et al. in italics in the text.
3. Please write full Journal name. Please write the volume and issue of references in the references list. Journal name and volume should be in italics.
4. Please check all your references according to Journal rules in <http://dergi.fabad.org.tr/information-for-authors/> link. References should be written according to American Psychological Association (APA) -6. For 6th edition of APA, "[http://calstatela.libguides.com/ld.php?content\\_id=39571710](http://calstatela.libguides.com/ld.php?content_id=39571710)" link can be followed.
5. You can also check the attached recent publication in our journal for reference writing style.

Regards,

Prof. Dr. Nesrin Gökhan Kelekçi

FABAD Journal of Pharmaceutical Sciences

Editor

yulia yusrini djabir <[yuliyusrini@yahoo.com](mailto:yuliyusrini@yahoo.com)>, 11 Ağu 2019 Paz, 14:48 tarihinde şunu yazdı:

Dear editor,

We are writing to express our interest to publish our manuscript in Fabad Journal of Pharmaceutical Sciences.

We attach the COVER LETTER, the CHECKLIST and the Manuscript with this email.

We also mention the three suggested reviewers in the cover letter.

I hope our manuscript is considered for publication in your journal.

Best regards,

Yulia Y. Djabir  
Laboratory of Clinical Pharmacy  
Faculty of Pharmacy  
Hasanuddin University  
Makassar  
Indonesia

## Re: FABAD A-592 Revision

---

From: yulia yusrini djabir (yuliyusrini@yahoo.com)

To: fabadankara@gmail.com

Date: Monday, 21 October 2019 at 04:26 pm GMT+8

---

Dear editor

I'd like to thank for the comments from the reviewers. We already address all the comments from reviewer 1 in the separate file, and we revised directly on the manuscript for comments from reviewer 2.

Best regards,  
Yulia Yusrini Djabir

On Saturday, 19 October 2019, 12:04:07 am GMT+8, FABAD Ankara <fabadankara@gmail.com> wrote:

**Dear Yulia Yusrini Djabir,**

Your manuscript (code: A-592) has been evaluated by the reviewers and the comments are given in the attached file. As you will see from the comments of the referees, your manuscript needs to be reevaluated. Attached please find the reviewer's comments for your submitted manuscript.

Kindly effect the recommended corrections and send it back within two weeks. The revised version of your manuscript will be sent to the same reviewers again, which means that a further evaluation of your contribution will be made. Final decision about acceptance or rejection is, therefore, still pending.

If the revised version is not submitted in time the manuscript will be withdrawn. Should you need additional time to prepare your review, please let us know.

**The revised manuscript should follow the guideline listed below:**

1. Response to the reviewers' comments should be on point by point basis and you should write your each answer just below the relevant comment of the reviewer in the word document I have mailed to you.
2. Also please indicate where changes have been made (with a **different highlighted color** in the text) in the revised manuscript.

Regards,

Prof. Dr. Nesrin Gökhan Kelekçi  
FABAD Journal of Pharmaceutical Sciences  
Editor

**Reviewer comments:**

**Reviewer 1.**

In the current study, the authors have investigated the time-dependent development of liver and renal damage induced by subchronic use of fixed dose combination of four

antituberculosis drugs (4FDC-AT) in rats.

Comments:

-Turkish grammar revision is required in öz section.

-There are a lot of abbreviations that are not defined the first time they are mentioned, for example ALT, CMC, NaCMC.

-How 28 days-drug treatment duration was determined?

-In addition to ALT, AST and/or ALP could be measured as an indicator of liver injury. Likewise, as biomarkers of kidney damage, some measurements such as BUN and creatinine clearance could be performed in blood and urine, respectively.

-Has any scale been used for histological examination of liver and kidney tissue with H&E staining? For example, Is grading performed in the assessment of inflammatory cell infiltration?

## **Reviewer 2.**

Corrections have been made on the manuscript.



A-592 Revision .docx  
23.1kB



FABAD A-592 Manuscript-Reviewer 2 Revised.docx  
3.3MB

## Re: FABAD A-592 Second Revision

---

From: yulia yusrini djabir (yuliyusrini@yahoo.com)

To: fabadankara@gmail.com

Date: Tuesday, 29 October 2019 at 02:26 pm GMT+8

---

Dear Editor,

I have revised the manuscript according to the reviewers' comments directly in the manuscript. The newest corrections are highlighted in yellow and pointed as "Aryadi Arsyad" comments (red).

Please let me know if I miss understood the instruction or if you want me to answer the correction point by point in another word file.

Best Regards,  
Yulia

On Sunday, 27 October 2019, 07:59:08 pm GMT+8, FABAD Ankara <fabadankara@gmail.com> wrote:

**Dear Yulia Yusrini Djabir,**

Your manuscript (code: A-592) has been reevaluated by the reviewers and the comments are given in the attached file. As you will see from the comments of the referees, your manuscript needs to be reevaluated. Attached please find the reviewer's comments for your submitted manuscript.

Kindly effect the recommended corrections and send it back within two weeks. The revised version of your manuscript will be sent to the same reviewers again, which means that a further evaluation of your contribution will be made. Final decision about acceptance or rejection is, therefore, still pending.

If the revised version is not submitted in time the manuscript will be withdrawn. Should you need additional time to prepare your review, please let us know.

**The revised manuscript should follow the guideline listed below:**

1. Response to the reviewers' comments should be on point by point basis and you should write your each answer just below the relevant comment of the reviewer in the word document I have mailed to you.
2. Also please indicate where changes have been made (with a **different highlighted color** in the text) in the revised manuscript.

Regards,

Prof. Dr. Nesrin Gökhan Kelekçi  
FABAD Journal of Pharmaceutical Sciences  
Editor

**Reviewer comments:**

**Reviewer 2.**

Corrections have been made on the manuscript.



FABAD A-592 Manuscript-Reviewer 2 Revision 2.docx  
3.3MB

Corrections have been made on the manuscript.



FABAD A-592 Manuscript-Reviewer 2 Revision 2.docx  
3.3MB

Re: proof of your manuscript

---

From: yulia yusrini djabir (yuliyusrini@yahoo.com)

To: fabadankara@gmail.com

Date: Monday, 3 February 2020 at 09:55 pm GMT+8

---

Dear Nesrin Dear Gökhan Kelekçi,

We are happy to receive your email. We have proofread the manuscript and the only thing we need to change is the position of the picture in figure 2. We understand that figure 2 needs to be organized horizontally, but unfortunately, it was a little bit off. We attach a landscape version of figure 2 to make it easier to be inserted into the article. I hope that can be helpful.

Thank you for considering to publish our article, looking forward to hearing from you.

Best regards,  
Yulia Yusrini Djabir

On Monday, 3 February 2020, 08:31:07 pm GMT+8, FABAD Ankara <fabadankara@gmail.com> wrote:

Dear Yulia Yusrini DJABIR,

You can find the attached proof of your accepted manuscript entitled "The Stages of Development of Liver And Renal Injuries in Rats Induced by Fixed Dose Combination of Antituberculosis Regimen (Code: A592)" and acceptance letter for FABAD Journal of Pharmaceutical Sciences. Please check the proof and make your corrections on pdf file. We will be greatfull if you could send us corrected proof in 5 days. Please make your correction on pdf file. It is very important not to change anything in the content. If you do, you should be aware that your review would need to go under second evaluation.

**P.S. Please check the format of your manuscript including references according to author's instructions. Unfited manuscripts will not be published.**

Acceptance letter of your manuscript is also attached.

Thank you very much for your kind interest.

Sincerely Yours,  
Nesrin Gökhan Kelekçi



FABAD A-592.pdf  
1.7MB



Figure 3a. copy.jpg  
2.1MB